Discover groundbreaking advancements in dermatology from the 2025 Fall Clinical Conference, featuring innovative treatments for psoriasis, alopecia, and atopic dermatitis.

Pfizer’s sigvotatug vedotin combined with Keytruda is being studied in patients with non-small cell lung cancer. Researchers suggest sigvotatug vedotin’s ability to induce immunogenic cell death may enhance antitumor activity.

To gain approvals, biosimilar manufacturers could do faster, less expensive analytical studies of their products' composition.

The medical director The US Oncology Network discusses adherence to clinical pathways, CAR-T therapy and concerns about the consequences of drug price negotiation under the IRA.

The Residual Transformer Generative Adversarial Network (RRTGAN) generates high-quality, cellular-level retinal images from minimal data inputs, overcoming the limitations of previous slow and burdensome imaging methods.

The findings challenge the conventional view that daytime sleepiness is always a result of insufficient sleep, poor sleep hygiene or classic sleep disorders.

In 2025, atopic dermatitis care evolved with new treatments, prioritizing holistic methods and personalized strategies for improved patient outcomes.

Researchers used nanoparticle technology to encapsulate paclitaxel and target bladder tumors more effectively. Early results demonstrate tumor elimination and minimal side effects.

Kyverna’s investigational CAR-T therapy, mivocabtagene autoleucel (miv-cel) showed clinically meaningful mobility improvements in most stiff-person syndrome patients, prompting the company to plan an FDA BLA submission in 2026.